Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 2, 2011, Pages 1111-1118

  Tan, Lay Ean ^a   Orilla, Werhner ^b   Hughes, Patrick M ^b   Tsai, Susan ^b   Burke, James A ^b   Wilson, Clive G ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE DEXTRAN; FLUORESCEIN SODIUM; HYALURONIDASE; DEXTRAN; DRUG DERIVATIVE; FLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE; HYALURONOGLUCOSAMINIDASE; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; FLUOROPHOTOMETRY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; RETINA ANGIOGRAPHY; SEDIMENTATION; SIMULATION; VITREOUS DISEASE; VITREOUS LIQUEFACTION; ANIMAL; CHEMICALLY INDUCED DISORDER; CONFOCAL MICROSCOPY; DISEASE MODEL; DRUG EFFECT; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; TISSUE DISTRIBUTION; VITREOUS BODY;

ANIMALS; DEXTRANS; DISEASE MODELS, ANIMAL; EYE DISEASES; FLUORESCEIN; FLUORESCEIN ANGIOGRAPHY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUOROPHOTOMETRY; HYALURONOGLUCOSAMINIDASE; INTRAVITREAL INJECTIONS; MICROSCOPY, CONFOCAL; MICROSPHERES; RABBITS; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 79953270200     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5813     Document Type: Article

References (34)

1. Sebag J. Macromolecular structure of the corpus vitreous. Prog Polym Sci. 1998;23:415-446.
2. Bishop PN. Structural macromolecules and supramolecular organization of the vitreous gel. Prog Retin Eye Res. 2000;19(3):323-344.
3. Balazs EA, Denlinger JL. Aging changes in the vitreous. Aging and Human Visual Function. New York: Alan R. Liss; 1982;45-47.
4. Sebag J. Balazs EA. Morphology and ultrastructure of human vitreous fibers. Invest Ophthalmol Vis Sci. 1989;30(8):1867-1871.
5. Sebag J, Balazs EA. Human vitreous fibres and vitreoretinal disease. Trans Ophthalmol Soc UK. 1985;104(Pt 2):123-128.
6. Sebag J. Age-related changes in human vitreous structure. Graefes Arch Clin Exp Ophthalmol. 1987;225:89-93.
7. Peeters L, Sanders NN, Braeckmans K, et al. Vitreous: a barrier to nonviral ocular gene therapy. Invest Ophthalmol Vis Sci. 2005;46: 3553-3561.
8. Pitkänen L, Ruponen M, Nieminen J, et al. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm Res. 2003;20(4):576-583.
9. Foulds WS, Allan D, Moseley H, et al. Effect of intravitreal hyaluronidase on the clearance of tritiated water from the vitreous to the choroid. Br J Ophthalmol. 1985;69:529-532.
10. Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol. 2007;245:576-580.
11. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased following vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135-2138.
12. Chin HS, Park TS, Moon YS, et al. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556-560.
13. Ficker L, Meredith TA, Gardner S, et al. Cefazolin levels after intravitreal injection. Invest Ophthalmol Vis Sci. 1990;31(3):502-505.
14. Stepanova LV, Marchenko IY, Sychev GM. Direction of fluid transport in the lens. Bull Exp Biol Med. 2005;139(1):50-51.
15. Harooni M, McMillan T, Refojo M. Efficacy and safety of enzymatic posterior vitreous detachment by intravitreal injection of hyaluronidase. Retina. 1998;18:16-22.
16. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina. 2000;20(2):195-198.
17. Wang ZL, Zhang X, Xu X, et al. PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina. 2005;25:38-43.
18. Tanaka M, Qui H. Pharmacological vitrectomy. Semin Ophthalmol. 2000;15:51-61.
19. Gottlieb JL, Antoszyk AN, Hatchell DL et al. The safety of intravitreal hyaluronidase, a clinical and histologic study. Invest Ophthalmol Vis Sci. 1990;31:2345-2352.
20. Winkler BS, Cohn EM. Hyaluronidase and retinal function. Arch Ophthalmol. 1985;103:1743-1746.
21. Pirie A. The effect of hyaluronidase injection on the vitreous humor of the rabbit. Br J Ophthalmol. 1949;33:678-684.
22. Narayanan R, Kuppermann BD. Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol. 2009;44:20-25.
23. Park J, Bungay PM, Lutz RJ, et.al. Evaluation of coupled convectivediffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release. 2005;105(3): 279-295.
24. Worst JGF, Los LI. Functional anatomy of the vitreous. Cisternal Anatomy of the Vitreous. Amsterdam: Kugler Publications; 1995; 33-48.
25. Stay MS, Xu J, Randolph TW, Barocas VH. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res. 2003;20(1):96-102.
26. Xu J, Heys JJ, Barocas VH, et al. Permeability and diffusion in vitreous humor: Implications for drug delivery. Pharm Res. 2000; 17(6):664-669.
27. Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways. Exp Eye Res. 1991;52:27-39.
28. Cunha-Vaz JG, Maurice DM. The active transport of fluorescein by the retinal vessels and the retina. J Physiol (Lond.) 1967;191:467-486.
29. Takahashi J, Hikichi T, Mori F, et al. Effect of nucleotide P2Y2 receptor agonists on outward active transport of fluorescein across normal blood-retina barrier in rabbit. Exp Eye Res. 2004;78(1): 103-108.
30. Dias CS, Mitra AK. Vitreal elimination kinetics of large molecular weight FITC-labeled dextrans in albino rabbits using a novel microsampling technique. J Pharm Sci. 2000;89:572-578.
31. Moldow B, Sander B, Larsen M, et.al. The effect of acetazolamide on passive and active transport of fluorescein across the bloodretina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol. 1998;236:881-889.
32. Spielberg L, Leys A. Intravitreal bevacizumab for hyopic choroidal neovascularization: short-term and 1-year results. Bull Soc Belge Ophtalmol. 2009;312:17-27.
33. Maurice D. Practical issues in intravitreal drug delivery (review). J Ocul Pharmacol Ther. 2001;17(4):393-401.
34. Giordano GG, Refojo MF, Arroyo MH. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol Vis Sci. 1993;34:2743-2751.